Soleno Therapeutics (SLNO) Net Cash Flow (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Net Cash Flow data on file, last reported at $62.9 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $62.9 million, up 1053.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.7 million (up 34.33% YoY), and the FY2025 annual result was -$17.8 million, up 78.2% from the prior year.
• Net Cash Flow climbed to $62.9 million in Q1 2026 per SLNO's latest filing, from -$176.6 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $170.2 million in Q3 2025 and troughed at -$176.6 million in Q4 2025.
• A 5-year average of $6.6 million and a median of -$4.3 million in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2024: Net Cash Flow jumped 2377.02% in 2023, then plunged 1785.17% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$5.1 million in 2022, then jumped by 2377.02% to $117.2 million in 2023, then sank by 66.3% to $39.5 million in 2024, then tumbled by 546.81% to -$176.6 million in 2025, then jumped by 135.64% to $62.9 million in 2026.
• Business Quant data shows SLNO's Net Cash Flow at $62.9 million in Q1 2026, -$176.6 million in Q4 2025, and $170.2 million in Q3 2025.